Dosage Lookup
Moderate
consensus
Dosage
Form
Timing
Notes
Huberman discusses rapamycin across 2 videos with a clear personal stance: he avoids it. In his dedicated longevity supplements AMA, he explicitly states he avoids metformin, berberine, and rapamycin, citing lack of sufficient human data for longevity and the presence of significant side effects. In his interview with Dr. David Fajgenbaum, rapamycin appears in the context of drug repurposing — Fajgenbaum discovered that sirolimus (rapamycin) could treat his terminal Castleman disease, which was originally approved for organ transplant rejection. This episode frames rapamycin as a powerful drug with multiple pathways but does not endorse it for longevity.
See exactly what each expert recommends — specific dosages, forms, timing protocols, and video citations with timestamps.
Cancel anytime